Quarterly ResultMay 7, 2026, 07:33 AM
Black Diamond to Present Silevertinib Phase 2 Data at ASCO; Cash $118.3M
AI Summary
Black Diamond Therapeutics reported a net loss of $9.0 million for Q1 2026, compared to a net income of $56.5 million in Q1 2025, with cash, cash equivalents, and investments of $118.3 million as of March 31, 2026, expected to fund operations into 2H 2028. The company announced an oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC at the 2026 ASCO Annual Meeting on May 30, 2026. Additionally, the first patient was dosed in the randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ GBM patients in May 2026.
Key Highlights
- Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC at ASCO on May 30, 2026.
- First patient dosed in randomized Phase 2 trial for newly diagnosed EGFRvIII+ GBM in May 2026.
- Cash, cash equivalents, and investments totaled $118.3 million as of March 31, 2026.
- Cash runway expected to fund operations into the second half of 2028.
- Net loss for Q1 2026 was $9.0 million, compared to net income of $56.5 million in Q1 2025.
- Research and development expenses decreased to $7.0 million in Q1 2026 from $10.5 million in Q1 2025.
- General and administrative expenses decreased to $4.3 million in Q1 2026 from $5.0 million in Q1 2025.
Price Impact
More from BDTX